A Multicenter, 6-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2b Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)

Date Added
April 27th, 2021
PRO Number
Pro00107203
Researcher
Deborah Bowlby

List of Studies


Keywords
Pediatrics
Summary

The standard treatment for growth hormone deficiency is daily injections under the skin of recombinant human growth hormone (rhGH). LUM-201 is an investigational drug (not approved by the US Food and Drug Administration) thought to increase the body's ability to release growth hormone. This study seeks to determine if oral LUM-201 at various doses may achieve similar catch-up growth compared to rhGH and provide a safe and effective treatment alternative to daily injections. Participant enrollment for the study will be for 8 months with 7 study visits.

Institution
MUSC
Recruitment Contact
Terry Headley
843.792.4629
headleyt@musc.edu



-- OR --